Antibody name | Targets | Clinical studies | Phase | Conditions |
---|---|---|---|---|
IMP321 | LAG-3 Fusion Protein | NCT00732082 | Phase I | Pancreatic neoplasms |
NCT03252938 | Phase I | Solid tumors | ||
NCT00351949 | Phase I | Stage IV renal cell Carcinoma | ||
NCT03625323 | Phase II | NSCLC, head and neck squamous cell carcinoma (HNSCC) | ||
NCT04252768 | Phase I | Metastatic breast cancer | ||
NCT00349934 | Phase I | Metastatic breast cancer | ||
NCT02614833 | Phase II | Adenocarcinoma breast | ||
NCT04811027 | Phase II | HNSCC | ||
Relatlimab | LAG-3 | NCT04080804 | Phase II | HNSCC |
NCT01968109 | Phase I/IIa | Neoplasms | ||
NCT02061761 | Phase I/IIa | Hematologic neoplasms | ||
NCT03610711 | Phase II | Gastroesophageal cancer | ||
NCT02658981 | Phase I | Glioblastoma | ||
NCT04150965 | Phase I/II | Multiple myeloma | ||
NCT03044613 | Phase Ib | Gastric cancer, Esophageal cancer, gastroesophageal cancer | ||
NCT04611126 | Phase I | Metastatic ovarian cancer, metastatic fallopian tube cancer, peritoneal cancer | ||
NCT03623854 | Phase II | Chordoma | ||
NCT03459222 | Phase I/II | Advanced cancer | ||
NCT02966548 | Phase I | Cancer | ||
NCT03662659 | Phase II | Gastric cancer, cancer of the stomach, esophagogastric Junction | ||
NCT03743766 | Phase II | Melanoma | ||
NCT04326257 | Phase II | Squamous cell carcinoma of the head and neck | ||
NCT04658147 | Phase I | Hepatocellular carcinoma | ||
NCT03607890 | Phase II | Cancer | ||
NCT04567615 | Phase II | Hepatocellular carcinoma | ||
NCT02519322 | Phase II | Melanoma | ||
NCT02060188 | Phase II | Microsatellite unstable colorectal cancer | ||
NCT03493932 | Phase I | Glioblastoma | ||
NCT02488759 | Phase I/II | Advanced cancer | ||
Sym022 | LAG-3 | NCT03489369 | Phase I | Metastatic cancer |
NCT04641871 | Phase I | Metastatic cancer | ||
NCT03311412 | Phase I | Metastatic cancer | ||
RO7247669 | PD-1 × LAG-3 | NCT04140500 | Phase I | Solid tumors |
NCT04785820 | Phase II | Advanced or metastatic esophageal Squamous cell carcinoma | ||
REGN3767 | LAG-3 | NCT03005782 | Phase I | Malignancies |
TSR-033 | LAG-3 | NCT03250832 | Phase I | Neoplasms |
EMB-02 | PD-1 × LAG-3 | NCT04618393 | Phase I/II | Advanced solid tumors |
MGD013 | PD-1 × LAG-3 | NCT03219268 | Phase I | Advanced solid tumors |
NCT04082364 | Phase II/III | Gastric cancer | ||
NCT04634825 | Phase II | Colorectal cancer | ||
NCT04129320 | Phase II/III | Head and neck cancer | ||
FS118 | PD-L1 × LAG-3 | NCT03440437 | Phase I/II | Advanced cancer |
INCAGN02385 | LAG-3 | NCT04370704 | Phase I/II | Melanoma |
TSR-033 | LAG-3 | NCT02817633 | Phase I | Neoplasms |
LAG525 | LAG-3 | NCT03365791 | Phase II | Advanced solid tumors, diffuse large B cell lymphoma |
NCT03742349 | Phase I | Triple negative breast cancer | ||
NCT02460224 | Phase I/II | Advanced solid tumors | ||
XmAb-22841 | CTLA-4 × LAG-3 | NCT03849469 | Phase I | Advanced solid tumors |
EOC202 | LAG-3 fusion protein | NCT03600090 | Phase I | Advanced solid tumors |